Epiomic Epidemiology Series: Acne Vulgaris Forecast in 15 Major Markets 2016-2026

Black Swan Analysis
72 Pages - BSA10084
$6,400.00

Acne, or Acne Vulgaris (AV), is a chronic inflammatory disease of the pilosebaceous unit. Although acne can develop at any age, it most commonly affects adolescents and is triggered by the overproduction of sebum in the sebaceous glands. Acne vulgaris is characterised by presence of comedones, papules, pustules, cysts, nodules and occasionally, scars. It can affect the face, anterior chest and upper back.

This report provides the current prevalent population for Acne Vulgaris across 15 Major Markets (USA, Canada, France, Germany, Russia, Italy, Spain, UK, Turkey, Poland, Australia, Japan, China, Brazil and India) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from our analysis team, several of the main symptoms and co-morbidities of Acne Vulgaris have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Acne Vulgaris include:

• Underlying hormone imbalance
• Puberty
• Family history
• Skin scarring

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Able to quantify patient populations in global Acne Vulgaris’s market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of Acne Vulgaris and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on Acne Vulgaris’s prevalent population.
• Identify sub-populations within Acne Vulgaris which require treatment.
• Gain an understanding of the specific markets that have the largest number of Acne Vulgaris disease patients.

'

Table of Contents
• List of Tables and Figures
• Introduction
• Cause of the Disease
• Risk Factors & Prevention
• Diagnosis of the Disease
• Variation by Geography/Ethnicity
• Disease Prognosis & Clinical Course
• Key comorbid conditions/Features associated with the disease
• Methodology for quantification of patient numbers
• Top-line prevalence for Acne Vulgaris
• Features of Acne Vulgaris patients
o Grade of Acne Vulgaris
o Severity of Acne Vulgaris
o Main type of Acne Vulgaris
o Papular-Pustular Acne Vulgaris
o Nodular-Cystic Acne Vulgaris
o Physiological Acne
• Predominant Features of Acne Vulgaris
o Nodules
o Comedones
o Pustules
o Oily Skin
o Propionibacterial Resistance
• Comorbid Conditions and Features of Acne Vulgaris
o Hyperplasia
o Type of Hyperplasia
o Family History
o Depression
o Premenstrual Flare
o Polycystic Ovary Syndrome
• Scarring in Patients with Acne Vulgaris
o Type of Scarring
• Location of Acne
• Other Black Swan Analysis Publications
• Black Swan Analysis Online Patient-Based Databases
• Patient-Based Offering
• Online Pricing Data and Platforms
• References
• Appendix


List of Tables
• Grading of Acne Vulgaris
• Prevalence of Acne Vulgaris, total (000s)
• Prevalence of Acne Vulgaris, males (000s)
• Prevalence of Acne Vulgaris, females (000s)
• Acne Vulgaris patients by Grade of severity, total (000s)
• Acne Vulgaris patients by Severity, total (000s)
• Acne Vulgaris patients by Main type, total (000s)
• Patients with Papular-Pustular Acne Vulgaris, total (000s)
• Severity of Papular-Pustular Acne Vulgaris, total (000s)
• Acne Vulgaris patients with Nodular-Cystic, total (000s)
• Acne Vulgaris patients with Physiological Acne, total (000s)
• Acne Vulgaris patients with Nodules, total (000s)
• Acne Vulgaris patients with Comedones, total (000s)
• Acne Vulgaris patients with Pustules, total (000s)
• Acne Vulgaris patients with Oily Skin, total (000s)
• Acne Vulgaris patients with Propionibacterial Resistance, total (000s)
• Acne Vulgaris patients with Hyperplasia, total (000s)
• Acne Vulgaris patients with Hyperplasia by type, total (000s)
• Acne Vulgaris patients with Family History, total (000s)
• Acne Vulgaris patients with Depression, total (000s)
• Acne Vulgaris patients with Premenstrual Flare, total (000s)
• Acne Vulgaris patients with POS, total (000s)
• Acne Vulgaris patients with Scarring, total (000s)
• Acne Vulgaris patients with Ice Pick Scarring, total (000s)
• Acne Vulgaris patients with Hypertrophy Scarring, total (000s)
• Acne Vulgaris patients with Atrophy Scarring, total (000s)
• Location of Acne Vulgaris within patients, total (000s)
• Abbreviations and Acronyms used in the report
• USA Prevalence of Acne Vulgaris by 5-yr age cohort, males (000s)
• USA Prevalence of Acne Vulgaris by 5-yr age cohort, females (000s)
• Canada Prevalence of Acne Vulgaris by 5-yr age cohort, males (000s)
• Canada Prevalence of Acne Vulgaris by 5-yr age cohort, females (000s)
• France Prevalence of Acne Vulgaris by 5-yr age cohort, males (000s)
• France Prevalence of Acne Vulgaris by 5-yr age cohort, females (000s)
• Germany Prevalence of Acne Vulgaris by 5-yr age cohort, males (000s)
• Germany Prevalence of Acne Vulgaris by 5-yr age cohort, females (000s)
• Russia Prevalence of Acne Vulgaris by 5-yr age cohort, males (000s)
• Russia Prevalence of Acne Vulgaris by 5-yr age cohort, females (000s)
• Italy Prevalence of Acne Vulgaris by 5-yr age cohort, males (000s)
• Italy Prevalence of Acne Vulgaris by 5-yr age cohort, females (000s)
• Spain Prevalence of Acne Vulgaris by 5-yr age cohort, males (000s)
• Spain Prevalence of Acne Vulgaris by 5-yr age cohort, females (000s)
• UK Prevalence of Acne Vulgaris by 5-yr age cohort, males (000s)
• UK Prevalence of Acne Vulgaris by 5-yr age cohort, females (000s)
• Turkey Prevalence of Acne Vulgaris by 5-yr age cohort, males (000s)
• Turkey Prevalence of Acne Vulgaris by 5-yr age cohort, females (000s)
• Poland Prevalence of Acne Vulgaris by 5-yr age cohort, males (000s)
• Poland Prevalence of Acne Vulgaris by 5-yr age cohort, females (000s)
• Australia Prevalence of Acne Vulgaris by 5-yr age cohort, males (000s)
• Australia Prevalence of Acne Vulgaris by 5-yr age cohort, females (000s)
• Japan Prevalence of Acne Vulgaris by 5-yr age cohort, males (000s)
• Japan Prevalence of Acne Vulgaris by 5-yr age cohort, females (000s)
• China Prevalence of Acne Vulgaris by 5-yr age cohort, males (000s)
• China Prevalence of Acne Vulgaris by 5-yr age cohort, females (000s)
• Brazil Prevalence of Acne Vulgaris by 5-yr age cohort, males (000s)
• Brazil Prevalence of Acne Vulgaris by 5-yr age cohort, females (000s)
• India Prevalence of Acne Vulgaris by 5-yr age cohort, males (000s)
• India Prevalence of Acne Vulgaris by 5-yr age cohort, females (000s)


$6,400.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838